NCT04334915View on ClinicalTrials.gov

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 22, 2022

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions
HIV Infections
Interventions
DRUG

Cenicriviroc Mesylate (CVC)

Administered orally

DRUG

Placebo

Administered orally

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH